| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1033780095 |
| P356 | DOI | 10.1038/SJ.GT.3300508 |
| P698 | PubMed publication ID | 9415313 |
| P5875 | ResearchGate publication ID | 13815566 |
| P50 | author | Jonathan L Bramson | Q45367604 |
| P2093 | author name string | Gauldie J | |
| Graham FL | |||
| Hitt M | |||
| P433 | issue | 10 | |
| P921 | main subject | Adenoviridae | Q193447 |
| vector-borne disease | Q2083837 | ||
| P304 | page(s) | 1069-1076 | |
| P577 | publication date | 1997-10-01 | |
| P1433 | published in | Gene Therapy | Q15763095 |
| P1476 | title | Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination | |
| P478 | volume | 4 |
| Q64377893 | "Man's best friend": a new model system for cancer therapeutics? |
| Q64377412 | A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer |
| Q40580007 | A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer |
| Q45859665 | Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial |
| Q33565630 | Adenoviral vector immunity: its implications and circumvention strategies |
| Q33744876 | Adenovirus vectors for gene delivery |
| Q45876450 | Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo |
| Q43785744 | Adenovirus-mediated wt-p16 reintroduction induces cell cycle arrest or apoptosis in pancreatic cancer |
| Q64905542 | An Oncolytic Adenovirus Vector Expressing p14 FAST Protein Induces Widespread Syncytium Formation and Reduces Tumor Growth Rate In Vivo. |
| Q54573260 | Anti-angiogenic effects of interleukin-12 delivered by a novel hyperthermia induced gene construct. |
| Q45856841 | Baculoviruses exhibit restricted cell type specificity in rat brain: a comparison of baculovirus- and adenovirus-mediated intracerebral gene transfer in vivo |
| Q38772887 | Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences. |
| Q36616672 | Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery |
| Q34759406 | Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial |
| Q45747425 | Complete cure of established murine hepatocellular carcinoma is achievable by repeated injections of retroviruses carrying the herpes simplex virus thymidine kinase gene |
| Q34585554 | Current strategies and future directions for eluding adenoviral vector immunity |
| Q37099738 | Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters |
| Q45883442 | Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12. |
| Q45867755 | Effective repeat administration with adenovirus vectors to the muscle |
| Q44305187 | Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines |
| Q45865369 | Enhanced local delivery with reduced systemic toxicity: delivery, delivery, and delivery. |
| Q45873183 | Enhancement of radiotherapy by hyperthermia-regulated gene therapy |
| Q39591041 | Expression of an antigenic adenovirus epitope in a group B coxsackievirus |
| Q37393759 | Expression of the fusogenic p14 FAST protein from a replication-defective adenovirus vector does not provide a therapeutic benefit in an immunocompetent mouse model of cancer. |
| Q44012459 | Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models |
| Q45880329 | Heat-inducible TNF-alpha gene therapy combined with hyperthermia using magnetic nanoparticles as a novel tumor-targeted therapy |
| Q36065620 | Human endostatin gene transfer, either naked or with liposome, has the same inhibitory effect on growth of mouse liver tumor cells in vivo |
| Q64379641 | Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity |
| Q33604559 | Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth |
| Q47277616 | Input virion proteins: cryptic targets of antivector immune responses in preimmunized subjects |
| Q35800342 | Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression |
| Q44192084 | Large nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes |
| Q37310677 | Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model |
| Q34269646 | Molecular therapeutics of liver disease |
| Q44808014 | On the role of CD4+ T cells in the CD8+ T-cell response elicited by recombinant adenovirus vaccines |
| Q34329548 | Oncolytic viruses as therapeutic agents |
| Q33817933 | Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo |
| Q37452136 | Persistence of transgene expression influences CD8+ T-cell expansion and maintenance following immunization with recombinant adenovirus |
| Q24799710 | Pharmacogenetic heterogeneity of transgene expression in muscle and tumours |
| Q33713048 | Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model |
| Q40519641 | Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus |
| Q56980888 | Recombinant Adenovirus Vaccines Can Successfully Elicit CD8+ T Cell Immunity under Conditions of Extreme Leukopenia |
| Q34361466 | Regulatable and cell-type specific transgene expression in glial cells: prospects for gene therapy for neurological disorders |
| Q36086213 | Replication-Competent Controlled Herpes Simplex Virus |
| Q56980983 | Super-activated interferon-regulatory factors can enhance plasmid immunization |
| Q40510406 | The human SCGB2A2 (mammaglobin-1) promoter/enhancer in a helper-dependent adenovirus vector directs high levels of transgene expression in mammary carcinoma cells but not in normal nonmammary cells |
| Q33857121 | The potential of gene therapy in the treatment of hepatocellular carcinoma |
| Q40587839 | Thyroid cancer immuno-therapy with retroviral and adenoviral vectors expressing granulocyte macrophage colony stimulating factor and interleukin-12 in a rat model |
Search more.